The Present and Future of the Adult Pneumococcal Vaccine Program in the United States-Reference-Cited by-同舟云学术

The Present and Future of the Adult Pneumococcal Vaccine Program in the United States

Published:2023-10-24 Issue:11 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Kobayashi Miwako¹,Cohen Adam L.¹,Poehling Katherine A.²

Affiliation:

1. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta

2. Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC

Publisher

Massachusetts Medical Society

Reference18 articles.

1. Kobayashi M. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. ACIP meeting presentation. October 20 2021 (https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/02-Pneumococcal-Kobayashi-508.pdf).

2. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper — February 2019;World Health Organization;Wkly Epidemiol Rec,2019

3. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023

4. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP);Advisory Committee on Immunization Practices;MMWR Recomm Rep,2000

5. Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for pneumococcal vaccination in older adults in the coming era;Human Vaccines & Immunotherapeutics;2024-03-22